Skip to content

Study Protocol for a Randomized Controlled Clinical Trial on Migraine Treatment with Mongolian Medical Brain-Shaking Therapy

Study Protocol for a Randomized Controlled Clinical Trial on Migraine Treatment with Mongolian Medical Brain-Shaking Therapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001403
Enrollment
Unknown
Registered
2026-06-03
Start date
2025-12-12
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

treatment group:Conventional treatment plus Mongolian medical brain-shaking therapy
control group:conventional drug therapy

Sponsors

Inner Mongolia International Mongolian Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the above diagnostic criteria for migraine without aura in both Mongolian medicine and Western medicine. (2) Aged 10-75 years, with no restriction on gender. (3) Headache attacks last for 4-72 hours (without treatment or with poor treatment effect). (4) Voluntarily participate in the study, sign the informed consent form, and be able to cooperate with treatment and follow-up.

Exclusion criteria

Exclusion criteria: (1) Complicated with severe diseases such as severe liver or kidney failure (ALT/AST > 2 times the upper limit of normal, Cr > upper limit of normal), heart failure, and malignant tumors. (2) Pregnant women, lactating women, or those planning to become pregnant. (3) Patients with severe traumatic brain injury (e.g., skull fracture, acute intracranial hemorrhage), disturbance of consciousness, or mental illness. (4) Patients with contraindications to brain-shaking therapy (e.g., intracranial space-occupying lesions, epilepsy, severe cerebrovascular malformation, etc.). (5) Patients allergic to trial drugs (e.g., flunarizine hydrochloride) or materials used in brain-shaking therapy. (6) Patients who have received other TCM/ethnic medical head treatments (e.g., acupuncture, tuina) or participated in other drug clinical trials within the past month. (7) Legally disabled patients (blind, deaf, mute, or with intellectual disability) or those with poor compliance (e.g., unable to return for follow-up visits on time).

Design outcomes

Primary

MeasureTime frame
number of migraine attack days;

Secondary

MeasureTime frame
Pain score (VAS);Mongolian Medicine Syndrome Score;Quality of life score (SF-36);

Countries

China

Contacts

Public ContactNashundalai

International Mongolian Hospital of Inner Mongolia

1045312506@qq.com13848913897

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 29, 2026